Tube Shunt Surgery: Ahmed vs. Baerveldt (What’s the Difference?)

While both the Ahmed and Baerveldt are effective at lowering eye pressure, they differ in design, flow regulation, and how they behave during the early recovery period.

The Ahmed valve is a valved device manufactured by New World Medical. Its built-in flow restrictor is designed to open when intraocular pressure (IOP) rises above approximately 8 mmHg, which helps maintain a safer pressure level in the days immediately following surgery. This makes the Ahmed a popular choice when the surgeon wants to minimize the risk of very low pressure in the early postoperative window. The trade-off is that the valve mechanism and smaller plate surface area may contribute to a higher long-term pressure compared to non-valved alternatives. The Ahmed is available in several sizes, with the FP7 model being the most widely used in adults.

The Baerveldt implant, manufactured by Johnson and Johnson Vision, is a non-valved device available in two plate sizes: 250 mm² and 350 mm². Because it lacks a flow restrictor, the surgeon ties off the tube with a dissolvable or removable suture at the time of surgery. This controlled delay allows the capsule to form around the plate before fluid begins flowing freely, reducing the risk of dangerously low pressure in the first few weeks. Once the suture releases, typically four to six weeks after surgery, the larger plate surface area of the Baerveldt often produces lower long-term eye pressure and less dependence on postoperative glaucoma medications.

The core distinctions between these two devices come down to flow regulation and plate size.

• The Ahmed has a built-in valve; the Baerveldt does not
• The Ahmed begins draining fluid immediately after implantation; the Baerveldt has a delayed drainage period due to a temporary suture
• The Baerveldt 350 has a larger plate surface area, which generally allows greater fluid absorption and lower long-term pressure
• The Ahmed tends to produce fewer early pressure fluctuations; the Baerveldt may carry a slightly higher risk of hypotony once flow begins

The procedure is performed under local anesthesia with sedation, typically on an outpatient basis. Your surgeon makes a small opening in the conjunctiva to access the sclera (the white wall of the eye), secures the plate to the surface of the eye, and inserts the tube through a small needle track into the anterior chamber. A patch graft, often made from donor tissue, is placed over the tube where it enters the eye to prevent erosion through the conjunctiva. The entire procedure usually takes 45 to 90 minutes depending on the complexity of your case.

Most patients can return to light daily activities within a few days, but full recovery takes several weeks to months. You will use antibiotic and anti-inflammatory eye drops for several weeks and attend frequent follow-up appointments so your surgeon can monitor pressure, check for complications, and adjust medications as needed. Vision may fluctuate during the first few months as the bleb matures and eye pressure stabilizes. Your recovery timeline depends on the device used, whether additional procedures were combined, and how your eye heals.

As with any surgical procedure, tube shunt surgery carries risks. The most common complications include hypotony, a hypertensive phase (a temporary pressure spike during healing), tube exposure through the conjunctiva, double vision, and corneal edema (swelling of the cornea from the tube's proximity). Less common but serious complications include infection (endophthalmitis), bleeding, retinal detachment, and device failure requiring removal or revision. Your surgeon will discuss your individual risk profile in detail before the procedure.

Both procedures create a new drainage pathway to lower eye pressure, but they use different mechanisms. Trabeculectomy creates a small flap in the wall of the eye that allows fluid to filter into a bleb, while a tube shunt uses a permanent silicone implant and plate system. The landmark Tube Versus Trabeculectomy (TVT) Study found that tube shunts had a higher success rate than trabeculectomy at five years in eyes that had undergone prior surgery. Trabeculectomy may still be preferred in certain first-time surgical cases because it can achieve very low pressures, but other options such as cyclophotocoagulation may also be considered depending on disease severity.

Tube shunt implants are designed to remain in the eye permanently and do not need routine replacement. Many patients maintain effective pressure control for years or even decades after surgery. However, the capsule of scar tissue around the plate can thicken over time, which may gradually reduce the device's drainage capacity. If pressure begins to rise again, your surgeon may adjust your medication regimen, perform a needling procedure to release scar tissue, or recommend additional surgery to regain control of your eye pressure.